proPSMA研究:镓-68 PSMA PET/CT用于高危前列腺癌根治性治疗前分期的前瞻性随机多中心临床试验方案
proPSMA试验为前瞻性多中心随机研究,纳入未治疗的高危前列腺癌患者,随机接受镓-68-PSMA-11 PET/CT或常规影像(腹盆CT+骨显像SPECT/CT),主要终点为淋巴结或远处转移检测准确性,由6个月组织病理、影像和临床随访按预设评分系统判定,并比较管理影响、不确定检查数、交叉后二线影像增量价值、成本、辐射暴露、观察者间一致性和安全性。
要点
- proPSMA试验旨在比较PSMA-PET/CT与常规影像在高危前列腺癌初始分期中的诊断准确性。
- 高危定义:ISUP分级组≥3(主要Gleason 4或任何Gleason 5)、PSA≥20 ng/mL或临床分期≥T3。
- 主要终点由6个月组织病理、影像和临床随访按预设评分系统判定。
核心结论
- 该试验将提供数据以确立PSMA-PET/CT是否应替代常规影像用于选择性高危局限性前列腺癌的初始分期,或仅用于提供增量诊断信息。
研究设计与样本
- proPSMA试验为前瞻性多中心随机研究,纳入未治疗的高危前列腺癌患者。
- 患者随机接受镓-68-PSMA-11 PET/CT或常规影像(腹盆CT和骨显像SPECT/CT)。
- 一线影像为阴性、不确定或寡转移的患者交叉接受另一影像臂。
关键数值与推荐
- 高危特征定义为ISUP分级组≥3(主要Gleason 4或任何Gleason 5)、PSA≥20 ng/mL或临床分期≥T3。
- 主要终点为比较PSMA-PET/CT与常规影像检测淋巴结或远处转移的准确性,由6个月组织病理、影像和临床随访按预设评分系统判定。
- 次要目标包括比较管理影响、不确定检查数、交叉患者二线影像增量价值、每种影像策略成本、辐射暴露、观察者间一致性和PSMA-PET/CT安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accurate staging of patients with prostate cancer (PCa) is important for therapeutic decision-making. Relapse after surgery or radiotherapy of curative intent is not uncommon and, in part, represents a failure of staging with current diagnostic imaging techniques to detect disease spread. Prostate-specific membrane antigen (PSMA) positron-emission tomography (PET)/computed tomography (CT) is a new whole-body scanning technique that enables visualization of PCa with high contrast. The hypotheses of this study are that: (i) PSMA-PET/CT has improved diagnostic performance compared with conventional imaging; (ii) PSMA-PET/CT should be used as a first-line diagnostic test for staging; (iii) the improved diagnostic performance of PSMA-PET/CT will result in significant management impact; and (iv) there are economic benefits if PSMA-PET/CT is incorporated into the management algorithm. OBJECTIVES AND METHODS: The proPSMA trial is a prospective, multicentre study in which patients with untreated high-risk PCa will be randomized to gallium-68-PSMA-11 PET/CT or conventional imaging, consisting of CT of the abdomen/pelvis and bone scintigraphy with single-photon emission CT/CT. Patients eligible for inclusion are those with newly diagnosed PCa with select high-risk features, defined as International Society of Urological Pathology grade group ≥3 (primary Gleason grade 4, or any Gleason grade 5), prostate-specific antigen level ≥20 ng/mL or clinical stage ≥T3. Patients with negative, equivocal or oligometastatic disease on first line-imaging will cross over to receive the other imaging arm. The primary objective is to compare the accuracy of PSMA-PET/CT with that of conventional imaging for detecting nodal or distant metastatic disease. Histopathological, imaging and clinical follow-up at 6 months will define the primary endpoint according to a predefined scoring system. Secondary objectives include comparing management impact, the number of equivocal studies, the incremental value of second-line imaging in patients who cross over, the cost of each imaging strategy, radiation exposure, inter-observer agreement and safety of PSMA-PET/CT. Longer-term follow-up will also assess the prognostic value of a negative PSMA-PET/CT. OUTCOME AND SIGNIFICANCE: This trial will provide data to establish whether PSMA-PET/CT should replace conventional imaging in the primary staging of select high-risk localized PCa, or whether it should be used to provide incremental diagnostic information in selected cases.
引用
- Hofman MS, Murphy DG, Williams SG, et al. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. BJU Int. 2018. PMID: 29726071. doi:10.1111/bju.14374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。